AstraZeneca announced the FDA accepted its supplemental application for IMFINZI plus enfortumab vedotin in muscle-invasive bladder cancer. The application received Priority Review, with a PDUFA date in Q4 2026, based on the VOLGA Phase III trial showing statistically significant improvements in event-free and overall survival.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
